Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.56 |
| ▸ | BLK | P51451 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | ITK | Q08881 | 2/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | TEC | P42680 | 1/20 | 0.52 |
| ▸ | TXK | P42681 | 1/20 | 0.52 |
| ▸ | BMX | P51813 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24458913 | 1.00 | BTK (0.56) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL24458544 | 0.91 | BTK (0.47) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL31523720 | 0.91 | BTK (0.47) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL31523992 | 0.88 | BTK (0.53) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL31523885 | 0.88 | BTK (0.53) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL24458766 | 0.88 | BTK (0.53) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL24458790 | 0.85 | BTK (0.52) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL24459061 | 0.83 | BTK (0.58) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL24458677 | 0.82 | BTK (0.39) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL31523783 | 0.82 | BTK (0.39) | BTKBLKEGFRITKERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | SRC, LCK, FYN | BTK 7/4885BLK 215/4885EGFR 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.